Cargando…

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry

PURPOSE: We aimed to evaluate quality of life (QoL) using the European Quality of Life Five-Dimensions questionnaire (EQ-5D-3L) in a real-world cohort of Dutch advanced breast cancer (ABC) patients. Secondary, we reported differences in QoL between subgroups of patients based on age, comorbidity, tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claessens, Anouk K. M., Ramaekers, Bram L. T., Lobbezoo, Dorien J. A., van Kampen, Roel J. W., de Boer, Maaike, van de Wouw, Agnes J., Dercksen, M. Wouter, Geurts, Sandra M. E., Joore, Manuela A., Tjan-Heijnen, Vivianne C. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686224/ https://www.ncbi.nlm.nih.gov/pubmed/32816222 http://dx.doi.org/10.1007/s11136-020-02604-4

Ejemplares similares

Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium
por: Seferina, Shanly C., et al.
Publicado: (2017)

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry
por: Meegdes, Marissa, et al.
Publicado: (2022)

The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry
por: Meegdes, Marissa, et al.
Publicado: (2021)

Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry
por: Meegdes, Marissa, et al.
Publicado: (2023)

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2021)

The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches
por: Lobbezoo, Dorien, et al.
Publicado: (2016)

Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands
por: Schneider, Paul Peter, et al.
Publicado: (2021)

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2023)

Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands
por: Schneider, Paul P., et al.
Publicado: (2020)

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
por: Lobbezoo, D J A, et al.
Publicado: (2015)

Healthcare Use during the Last Six Months of Life in Patients with Advanced Breast Cancer
por: Schmitz, Renée. S. J. M., et al.
Publicado: (2021)

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
por: van Hellemond, Irene E. G., et al.
Publicado: (2018)

Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience
por: Vriens, Ingeborg J. H., et al.
Publicado: (2020)

The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer
por: Claessens, Anouk K. M., et al.
Publicado: (2019)

Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer
por: van Abbema, Doris, et al.
Publicado: (2019)

Characteristics of triple-negative breast cancer
por: de Ruijter, Tim C., et al.
Publicado: (2010)

Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling
por: Angus, Lindsay, et al.
Publicado: (2023)

The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients
por: Vriens, Ingeborg J.H., et al.
Publicado: (2017)

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies
por: Vriens, Birgit E.P., et al.
Publicado: (2017)

Associations of hospital volume and hospital competition with short-term, middle-term and long-term patient outcomes after breast cancer surgery: a retrospective population-based study
por: van der Schors, Wouter, et al.
Publicado: (2022)

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors
por: Truin, Wilfred, et al.
Publicado: (2017)

What to Do with Non-visualized Sentinel Nodes? A Dutch Nationwide Survey Study
por: Verheuvel, Nicole C., et al.
Publicado: (2017)

Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer
por: Pouwels, Xavier Ghislain Léon Victor, et al.
Publicado: (2017)

Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
por: Otten, Thomas Michael, et al.
Publicado: (2023)

Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer
por: van Waalwijk, Maren A., et al.
Publicado: (2011)

Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure
por: Verheuvel, Nicole C., et al.
Publicado: (2017)

Geriatric screening tools are of limited value to predict decline in functional status and quality of life: results of a cohort study
por: Deckx, Laura, et al.
Publicado: (2015)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands
por: Luiten, Jacky D., et al.
Publicado: (2021)

Frequency and diagnostic outcome of bilateral recall at screening mammography
por: Lameijer, Joost R. C., et al.
Publicado: (2020)

Impact of the second reader on screening outcome at blinded double reading of digital screening mammograms
por: Coolen, Angela M. P., et al.
Publicado: (2018)

CD44 enhances tumor aggressiveness by promoting tumor cell plasticity
por: Paulis, Yvette W.J., et al.
Publicado: (2015)

The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study
por: de Ruijter, Tim C., et al.
Publicado: (2019)

The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy
por: Manders, P, et al.
Publicado: (2002)

Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study
por: van Hellemond, Irene E.G., et al.
Publicado: (2019)

Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial
por: van Hellemond, Irene E. G., et al.
Publicado: (2020)

Clinical value of contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: a population-based cohort study
por: Keymeulen, Kristien B. I. M., et al.
Publicado: (2022)

Delayed breast cancer diagnosis after repeated recall at biennial screening mammography: an observational follow-up study from the Netherlands
por: Lameijer, Joost R. C., et al.
Publicado: (2020)

High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer
por: van Oostwaard, Marsha M., et al.
Publicado: (2022)

Updated Incidence, Treatment and Survival of a Nationwide Cohort of Patients with Peritoneal Metastases of Unknown Origin
por: Rijken, Anouk, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k9rdgcjc5260kauc05tbn4u5e6